Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Merck KGaA May Withdraw Research from Portugal over Debt-Report

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/09/2012 | 08:28am CEST

German chemical company Merck KGaA (>> Merck KGaA) may withdraw future investments for research projects in Portugal worth tens of millions of euros unless the government hospitals stick to the agreed-upon debt repayments, German daily newspaper Financial Times Deutschland reports Monday.

Merck Portugal's manager Fritz Sacher told the paper the company's research projects are long-term and require mutual trust as a basis. "The Portuguese government's lacking payment habits undermine this trust," he is quoted as saying.

Portuguese government hospitals owe the pharmaceutical industry a total of more than 1.5 billion euros ($1.84 billion) and companies have to wait nearly 550 days on average until invoices are paid, FTD reports.

Some companies, including Roche Holding AG (ROG.VX), have already halted the sale of medications on credit to highly indebted countries like Portugal, Greece, Spain and Italy until outstanding debts are paid, the paper notes, but for many companies such drastic steps are difficult as they carry responsibility for people's wellbeing.

Withdrawing research projects is a way of putting pressure on the government, as Portugal is an attractive location for research investments, FTD says. "The conditions for certain research and human studies are as good as in the U.S., but it's significantly more cost-effective in Portugal," Sacher told the paper.

Newspaper website: http://www.ftd.de

Write to the Frankfurt Bureau at [email protected]

Stocks mentioned in the article : Merck KGaA
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
06/22 MERCK : Human Longevity, Inc. Announces Agreement with Merck KGaA, Darmstadt, Ge..
06/15 MERCK KGAA : Darmstadt, Germany, Strengthens Immuno-Oncology Portfolio through E..
06/14 PFIZER : German Merck Doubles Down On Dual-Acting Cancer Agents
06/13 Progesterone Market 2017 - Pfizer, Solvay, ASEN, SENZU, Actavis, Merck Serono..
06/09 MERCK KGAA : Darmstadt, Germany, Selects illusive networks' Deceptions Everywher..
06/09 MERCK : EMD Serono Honors World MS Day by Launching Care Partner Survey with IAC..
06/09 MERCK KGAA : Darmstadt, Germany Licenses Selexis SUREtechnology Platform for Imm..
06/04 MERCK : Strengthens Immuno-Oncology Portfolio through Expansion of F-star Collab..
06/02 MERCK : SCHOOLS Memorial Park School to host STEM Fair
06/01 MERCK : EMD Serono to Present Data Highlighting Investigational Cladribine Table..
More news
Sector news : Specialty & Advanced Pharmaceuticals
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
06/23DJSAMSUNG ELECTRONICS : Makes Big Play in Drug Market With Cheaper Version of Bloc..
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/23 China's ICBC says checks of loans to big acquirers are routine
06/22 GSK'S NEW CEO AIMS TO DIVEST SPORTS : sources
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
06/15 Therapy Focus - Lupus Hopes Build But Data Remain On The Distant Horizon
06/13 German Merck Doubles Down On Dual-Acting Cancer Agents
06/06 Merck Reveals Its Gastric Cancer Hand
06/05 Deciphering The Immunology Combo Avalanche
05/18 Merck's (MKGAF) on Q1 2017 Results - Earnings Call Transcript
Advertisement
Financials (€)
Sales 2017 15 596 M
EBIT 2017 3 382 M
Net income 2017 1 840 M
Debt 2017 9 581 M
Yield 2017 1,14%
P/E ratio 2017 25,92
P/E ratio 2018 22,18
EV / Sales 2017 1,54x
EV / Sales 2018 1,36x
Capitalization 14 436 M
More Financials
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 113 €
Spread / Average Target 1,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stefan Oschmann Chief Executive Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA12.66%16 118
ABBVIE13.93%116 469
KYOWA HAKKO KIRIN CO L..28.74%10 696
JAZZ PHARMACEUTICALS P..46.27%9 583
CONVATEC GROUP43.39%8 292
ZHANGZHOU PIENTZEHUANG..27.19%4 998
More Results